Loading
A phase 2 trial of SHR-A2102, Retlirafusp alfa in non-small-cell lung cancer and small-cell lung cancer, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.
Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects is a phase 2 interventional study registered as NCT07175220 by Jiangsu HengRui Medicine Co., Ltd., with 200 participants planned, started 2025-10-09 and due to reach its primary completion in 2028-10. Interventions recorded: SHR2554; SHR-A2102, SHR2554; Adabelimumab, SHR2554; SHR-1701. Conditions listed: Locally Advanced or Metastatic Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares SHR-A2102, Jiangsu Hengrui Pharmaceuticals, Small-cell lung cancer, Non-small-cell lung cancer.
Shares SHR-A2102, Jiangsu Hengrui Pharmaceuticals.
Shares SHR-A2102, Jiangsu Hengrui Pharmaceuticals, Small-cell lung cancer, Non-small-cell lung cancer.
Shares SHR-A2102, Jiangsu Hengrui Pharmaceuticals, Small-cell lung cancer, Non-small-cell lung cancer.
Shares SHR-A2102, Jiangsu Hengrui Pharmaceuticals.
Shares Jiangsu Hengrui Pharmaceuticals, Small-cell lung cancer, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/